<DOC>
	<DOC>NCT00996918</DOC>
	<brief_summary>The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.</brief_summary>
	<brief_title>A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subject has completed study 3133K13000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease MiniMental Status Examination (MMSE) &gt;=10 at screening Caregiver able to attend all clinic visits with subject Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response. Any significant brain MRI abnormality. Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>antibody</keyword>
</DOC>